Johnson & Johnson vs Kymera Therapeutics, Inc. — Stock Comparison
Johnson & Johnson (JNJ) and Kymera Therapeutics, Inc. (KYMR) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson scores ahead of Kymera Therapeutics, Inc. on Q·Score (6.6 vs 5.4 out of 10), led by Quality (8.5 vs 2.1) and Valuation (5.8 vs 4.2). Kymera Therapeutics, Inc. scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for KYMR (+11.8%) than for JNJ (+2.3%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 20% return on equity and 16% profit margins.
⚠ earnings contracting 96% year-over-year.
Clean balance sheet with low leverage (0.0× debt-to-equity).
⚠ low return on equity (-27%).
Analyst Consensus
Fundamentals
Frequently Asked Questions
JNJ vs KYMR: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 6.6/10 versus Kymera Therapeutics, Inc. (KYMR) at 5.4/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: JNJ or KYMR?
Kymera Therapeutics, Inc. (KYMR) scores higher on Growth (5/10 vs 4.3/10). Johnson & Johnson reports revenue growth (5.9% YoY) while Kymera Therapeutics, Inc. reports. Growth scores reflect revenue and earnings momentum relative to sector peers.
Is JNJ or KYMR more attractively valued?
Johnson & Johnson (JNJ) scores higher on Valuation (5.8/10 vs 4.2/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about JNJ vs KYMR?
There are 22 analysts covering JNJ with a consensus price target of $279.41, and 23 analysts covering KYMR with a consensus target of $141.61. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: JNJ or KYMR?
Johnson & Johnson (JNJ) scores higher on Quality (8.5/10 vs 2.1/10). Net profit margin: JNJ at 16.2%, KYMR at 0.0%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: JNJ or KYMR?
Kymera Therapeutics, Inc. (KYMR) scores higher on Financial Health (8.7/10 vs 6.5/10). Market beta: JNJ at 0.21, KYMR at 1.98. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of JNJ and KYMR?
Johnson & Johnson (JNJ) has a market capitalisation of $657.7B, while Kymera Therapeutics, Inc. (KYMR) has a market cap of $10.8B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do JNJ or KYMR pay dividends?
JNJ pays a dividend yield of 1.96%, while KYMR does not currently pay a dividend. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →